Severe hyperinsulinism can be treated with somatostatin analogues. We studied growth and growth hormone(gh) in a patient with nesidioblastosis,treated with SMS 201-995. In a maroccan female with nesidioblastosis subtotal pancreatectomy was performed at an age of 4 weeks. Because of recurrent hypoglycaemia SMS 201-995 was instituted from an age of 1 1 month till 3.1 yrs.In a dose of 8 x 25pglday s.c. SMS 201-995resulted in normoglycaemia(portab1e infus~on pump.Ferring). The SMS treatment could be ceased at an age of 3.1 yrs. Growth velocity during the last 6 months of treatment was 5.2 cmlyr. In the year after discontinuation of therapy growth vel. increased to 12.2 cn yr.(CA:4.0 yr). During treatment SMC level was normal to slight1 elevated(l62 nglmL); maximum gh level during sleep decreased with the treatment period and was 8.2pgIL. just before discontinuntion.14 days off treatment max.gh had increased to 13yglL. Conclusion: Chronic subcutaneous therapy(2.2 yrs) of SMS 201-995 was succesfull in preventing hypoglycaemic periods in a girl wit11 nesidioblastosis. Growth hormone secretion was gradually impaired during treatment. Catch up growth after discontinuation of therapy makes evident that growth was impaired during treatment with the somatostatin analogue SMS 201-995.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.